

HAEMONETICS CORP  
Form 8-K  
October 27, 2008

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

WASHINGTON, D.C. 20549

---

**FORM 8-K**

**CURRENT REPORT**  
**Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): **October 23, 2008**

**HAEMONETICS CORPORATION**

(Exact name of registrant as specified in its charter)

**Massachusetts**  
(State or other jurisdiction  
of incorporation)

**1-10730**  
(Commission  
File Number)

**04-2882273**  
(IRS Employer  
Identification No.)

**400 Wood Road**  
(Address of principal executive offices)

**02184**  
(Zip Code)

Registrant's telephone number, including area code: **781-848-7100**

(Former name or former address, if changed since last report)

## Edgar Filing: HAEMONETICS CORP - Form 8-K

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

***Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.***

On October 23, 2008 the Company's Board of Directors decided that Brian Concannon will be promoted to the position of President and CEO effective in April, 2009, succeeding Brad Nutter in this role. Mr. Concannon will also join the Company's Board of Directors at that time. Mr. Nutter will relinquish his role as President and CEO of the Company concurrently with Mr. Concannon's assumption of those offices, and Mr. Nutter will remain an employee of the Company as Executive Chairman of the Company's Board of Directors.

Mr. Concannon (age 51) joined Haemonetics in September, 2003 as President of the Patient Division, following an eighteen year career with progressively responsible leadership roles with American Hospital Supply Corporation, Baxter Healthcare Corporation, Allegiance Healthcare and Cardinal Health Products and Services. In 2006, Mr. Concannon was promoted to President of Global Markets at Haemonetics, and in 2007 he was promoted to Chief Operating Officer of the Company.

***Item 9.01 Financial Statements and Exhibits***

(d) Exhibits.

99.1 *Press Release of Haemonetics Corporation dated October 27, 2008.*

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

HAEMONETICS CORPORATION  
{Registrant}

Date: October 27, 2008

/s/ Christopher J. Lindop  
Christopher J. Lindop,  
Chief Financial Officer and  
Vice President Business Development

**EXHIBIT INDEX**

99.1 Press Release of Haemonetics Corporation dated October 27, 2008.